By Hilary Rosselot
Healx Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Wayne Chadwick, a Principal Pharmacologist at Healx Ltd., presented about the IMPACT-FXS trial during the Industry Updates keynote session at the 18th International Fragile X Conference.
IMPACT-FXS is a Phase 2 trial targeting multiple pathways associated with Fragile X to maximize the number of behaviors treated in individuals with Fragile X syndrome.
Wayne shared more about Healx, their novel AI approach to finding treatments, and their Phase 2 trial. Learn more about Healx and the IMPACT-FXS trial by watching their 2022 Industry Updates presentation or vising their MyFXResearch post.
about
![Author Hilary Rosselot](https://fragilex.org/wp-content/uploads/Rosselot-Hilary-contact.jpg)
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
POcKIT Study: At-Home Study for Young Children with FXS
Purdue University is conducting a research study to learn about how genetic, biological, nutritional, and environmental information relates to health and development in Fragile X syndrome.
Benefit of BPN14770 for Cognition and Daily Function in Fragile X Syndrome
Your summary of the results, including why it matters to you and next steps, from the Dr. Liz Berry-Kravis and Tetra Therapeutics BPN14770 trial results published in Nature Medicine. This was a randomized, double-blind, placebo-controlled, two-period crossover study.